Research programme: inflammatory bowel disease CAR-T cell therapies - Sonoma Biotherapeutics
Alternative Names: SBT-77-7200 seriesLatest Information Update: 18 Aug 2021
At a glance
- Originator Sonoma Biotherapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Inflammatory bowel diseases